



Immune Design
Investor Relations Department
Immune Design Corp. Attn:
Accounts Payab
601 Gateway Blvd. Suite 250
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

Last Trade:	11.95
Trade Time:	4:00 PM ET Jul 27, 2017
Change:	0.30 ↑ (+2.575%)
Day Range	11.58 - 13.05
52-Week Range	4.50 - 11.75
Volume	443,387

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 26, 2017*
[Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update](#)
- Jun 5, 2017*
[Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting](#)
- Jun 1, 2017*
[Immune Design to Present at Jefferies 2017 Global Healthcare Conference](#)
- May 17, 2017*
[New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms](#)
- May 17, 2017*
[Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update](#)

Upcoming Events [\[View all \]](#)

- Aug 2, 2017 1:30 PM PT*
[Immune Design Second Quarter 2017 Financial Results](#)
- Financials** [\[View all \]](#)
[First Quarter Financial Results](#)
- Mar 7, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*
[Quarterly Report \(10-Q\)](#)